Despite YM155 being one of the most well-studied survivin inhibitors for glioblastoma multiforme, inhibition of the IAP protein may also be approached through inducing survivin mutations, siRNA interference, and additional pharmacotherapeutic agents, as highlighted in Table 1. The gene discussed is BIRC5; the disease is glioblastoma.